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INTRODUCTION
Lung cancer is a major cause of cancer deaths worldwide (1)
and has become the leading cause of cancer deaths in Korea
(2). Advances in cancer treatment in the past two decades
have contributed to only minimal increase in survival rates
of patients with non-small cell lung cancer (NSCLC) (3). Des-
pite apparent complete resection of the primary tumor, recur-
rence rates remain high and the overall 5-yr survival remains
poor with <15% of patients surviving 5 yr from diagnosis
(1). Some tumors, regardless of clinically favorable staging,
are quite aggressive and progress to fatal disease. This implies
that the TNM staging of NSCLC may be an acceptable, but
not a satisfactory, classification system. Recent molecular stud-
ies have provided increased understanding of the biology of
lung cancer and have identified multiple factors responsible
for the modulation of tumor growth and the prognosis (4-6).
Nevertheless, the essential genetic features, along with fac-
tors for prognosis, have yet to be fully understood.
Altered regulation of the cell cycle is a hallmark of human
cancers (6). The cell cycle is governed by cdks. An important
mechanism for regulating the cdk activity involves the cdk
inhibitors, which are organized into two families based on
structure and function: the Cip/Kip family (p21, p27, p57)
and the INK4 family (p16, p18, p19). Cyclin E/cdk2 com-
plex is an important regulator of entry into the S phase of
the cell cycle, whereas cyclin B1/cdc2 is the classic M phase-
promoting factor that drives entry into mitosis (7-10). Ki-67
proliferative index appears to be associated with survival in
patients with various malignancies, but results are conflicting
for NSCLC. Apoptosis or programmed cell death is a crucial
mechanism of cellular homeostasis in organisms (11-14). One
of the hallmark features of cancer cells is their ability to evade
apoptosis. Angiogenesis is the process by which new capil-
lary beds are formed from preexisting vessels, and is impor-
tant in tumor growth (15). Vascular endothelial growth fac-
tor (VEGF) is a potent growth factor for endothelial cells (16).
Tumors may activate angiogenic inhibitors such as angio-
statin and endostatin, which control growth by suppressing
endothelial cell proliferation and angiogenesis and by indi-
rectly increasing apoptosis in tumor cells (17). 
In the present study, we used the high-throughput tissue
microarray (TMA) technology combined with immunohis-
tochemistry (IHC) analysis (18, 19) to define the clinical sig-
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Immunohistochemical Analysis of Non-Small Cell Lung Cancer: 
Correlation with Clinical Parameters and Prognosis
Non-small cell lung cancers (NSCLC) vary in their biologic behavior. Recurrence
and tumor-related mortality may be attributable to molecular abnormalities in prima-
ry tumors. This study evaluated such immunophenotypes with regard to cell cycle
regulation and proliferation, apoptosis, and angiogenesis, to determine their signifi-
cance for patient outcome. Core biopsies from 219 patients with NSCLC were as-
sembled on tissue microarrays, and the expressions of p16, p21, p27, cyclin B1,
cyclin E, Ki-67, caspase-3, survivin, bcl-2, VEGF, and endostatin were evaluated
by immunohistochemistry. Despite previously described prognostic relevance of
some of the investigated molecules, many of those markers were not directly asso-
ciated with recurrence or survival. However, there was a trend for p16 immunore-
activity to be associated with a good prognosis (57% vs. 42% in 5-yr survival) (p=
0.071). bcl-2 expression was strongly correlated with a better outcome (65% vs.
45% in 5-yr survival) (p=0.029), and the hazard of death for bcl-2 positive patients
was 0.42 times of that for bcl-2 negative patients (p=0.047). A multivariate analysis
with Cox proportional hazards model confirmed that the lymph node status (p=0.043)
and stage (p=0.003) were other independent prognostic factors. Our results sug-
gest that p16 and bcl-2 provide prognostic information independent of the TNM
stage in NSCLC. 
Key Words : Carcinoma, Bronchogenic; Cell Cycle; Apoptosis; Angiogenesis Factor; Prognosis
Received : 8 August 2006
Accepted : 2 October 2006Immunohistochemical Analysis of NSCLC 319
nificance of altered expression of cell cycle regulatory or pro-
liferation-related, apoptotic, and angiogenic factors. Immu-
nophenotypes were correlated with patient outcome to deter-
mine their prognostic value.
MATERIALS AND METHODS
Patients 
Two hundred and nineteen patients with previously un-
treated NSCLC were included in this study. The study pro-
tocol was reviewed and approved by the Institutional Review
Board at the Catholic University St. Vincent’s Hospital. All
patients underwent surgical resection at the Department of
Thoracic Surgery. The patients were staged at the time of
their surgery following the guidelines of the American Joint
Committee on Cancer Staging (20). Clinical information was
obtained through a computerized retrospective database of
tumor registry. Patients who died within one month after
surgery were excluded from the study to avoid bias of peri-
operative mortality. Only patients with stages I to IIIA dis-
ease and microscopically negative resection margins were
included in this study. Patients did not receive neoadjuvant
chemotherapy or radiotherapy. The survival duration was
determined from the date of surgery for the primary lung
cancer to date of last follow-up or date of death from lung
cancer. Follow-up ranged from 1.6 to 117.8 months (medi-
an 38.9 months). Eighty-seven patients (39.7%) died dur-
ing follow-up, and 132 were alive at the time of this study. 
Histologic examination and TMA construction
Hematoxylin and eosin stained slides were reviewed for
confirmation of histopathologic diagnosis and for selection
of adequate specimens for analysis. Histologic typing was
performed according to the histological classification of lung
cancer by the World Health Organization (21). When the
tumors are composed of cells resembling the mature normal
cells of the tissue of origin of the neoplasm, they were con-
sidered as well differentiated, and when the tumors have prim-
itive-appearing, unspecified cells, they were considered as
poorly differentiated.
Areas of viable, representative tumor were identified and
marked by a pathologist (JY) for the construction of microar-
rays. Three to four cores, each measuring 2.0 mm in diame-
ter, were sampled from different areas of the tumor with a
precise instrument and were arrayed on a recipient paraffin
block. 
Immunohistochemistry 
For immunohistochemical staining, a sensitive peroxidase-
streptavidin method, as described previously, was performed
using four- m sections of these array blocks. First sections
were stained for H&E to verify histology. 
The antibodies for cell cycle regulation used in this study
were p16 (clone 16P07, NeoMarkers, Fremont, CA, U.S.A.),
p21 (clone EA10, Zymed, San Francisco, CA, U.S.A.), p27
(NeoMarkers), cyclin E (clone 13A3, NeoMarkers), and cyclin
B1 (clone GNS11, NeoMarkers). Proliferative activity was
determined using anti-Ki-67 (clone 7B11, Zymed). The anti-
bodies to detect the apoptotic factors were caspase-3 (clone
3CSP03, NeoMarkers), survivin (clone 4F7, NeoMarkers),
and bcl-2 (clone bcl-2-100, Zymed). The antibodies for stain-
ing of angiogenic factors were VEGF (clone A20, Santa Cruz
Biotechnology, Heidelberg, Germany), and endostatin (clone
1837-46, NeoMarkers).
Briefly, tissues cut from microarrays were deparaffinized
in xylene and rehydrated in graded alcohols and water. En-
dogenous peroxidase was blocked by soaking in 3% H2O2
at 45℃ for 4 min. The slides were microwaved in citrate
buffer (2.1 g/L, pH 6.0) at 120℃ for 15 min to unmask the
antigen, and treated with a protein-blocking reagent before
incubation at 4℃ overnight with primary antibodies at a
1:50 dilution, as recommended by the supplier. After exten-
sive washing, the sections were incubated at room tempera-
ture for 10 min with biotinylated anti-mouse immunoglob-
ulin antibodies (Zymed, San Francisco, CA) at a 1:20 dilu-
tion and subsequently with streptavidin-biotin peroxidase
complexes at a 1:25 dilution. Reaction products were visu-
alized by immersing slides in 3,3′ -diaminobenzidine tetrahy-
drochloride. Counterstaining was performed with hemato-
xylin. All series included positive and negative controls. Nega-
tive controls were prepared by omitting the primary antibod-
ies and known positive controls were included in each run.
Three investigators independently evaluated the results
from the immunohistochemical staining in a blinded fash-
ion and obtained the identical results in 92% of the cases. For
the discordant samples, slides were reviewed jointly and a
consensus was reached. For the evaluation of immunoreactiv-
ity in tumor cells, a dichotomised scoring system was used as
follows: p16 positivity if >80% of tumor cells demonstrat-
ed either nuclear or cytoplasmic staining; p21 positivity if
>5% tumor nuclei stained; p27 positivity if >20% of tumor
nuclei stained; high Ki-67 labeling index and high cyclin E
labeling index if >30% tumor cells stained; caspase-3 posi-
tivity if nuclear or cytoplasmic staining was present in >25%
of tumor cells; survivin or bcl-2 positivity if >10% tumor
cell stained; VEGF expression if >5% of tumor cells stained;
endostatin positivity if scores between 3 and 6 (the sum of
the percentage of tumor cells [0, 1=<25%, 2=26-50%, 3=
>50%] and the staining intensity [1-3]) (9, 12, 18, 22-26).
Statistical analysis
Statistical analysis was carried out using a software pack-
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estimated using the Kaplan-Meier method and then com-
pared with the log rank test. The influence of various clini-
copathologic variables on the survival was assessed with the
Cox proportional hazards model. The level of significance
was set at p<0.05.
RESULTS
Clinicopathologic data
Complete clinical and histologic data were available for
all patients. One hundred and sixty-eight patients (76.7%)
were male and the mean age was 65.8 yr (SD 9.9; median
67; age range 19-89). Patient characteristics are shown in
Table 1. 
Immunohistochemistry
A significant variation was present in the expression of the
individual immunohistochemical markers in tumor tissues.
The highest rate of positivity was noted for VEGF in 92.7%
of the tumors. The lowest rate of expression was observed with
survivin in 2.7% of the samples. The expression profiles of
all markers are presented in Table 2. 
Of the cell-cycle regulation and proliferation-related pro-
W, well differentiated; M, moderately differentiated; P, poorly differenti-
ated.
No. of patients
(N=219)
Variables %
Age (yrs)
Mean (SD) 65.8±9.9
<65 92 42
≥65 127 58
Gender
Male 168 76.7
Female 51 23.3
Histology 
Squamous cell carcinoma (W/M/P) 100 (4/79/17) 45.7
Adenocarcinoma (W/M/P) 119 (29/64/26) 54.3
T status
T1 57 26
T2 123 56.2
T3 39 17.8
Regional lymph node status
N0 141 64.4
N1 51 23.3
N2 27 12.3
Clinical stage
I 135 61.6
II 25 11.4
III 59 26.9
Table 1. Clinicopathologic charateristics
Variables No.
No. of positive cases 
p16 p21 p27 Cyclin 
B1
Cyclin
E
Cas-
pase
Sur-
vivin
Bcl-2 VEGF
Endo-
statin
Ki-67
Histology
Squamous cell carcinoma 100 22 71 22 4 43 36 3 19 93 94 11
Well differentiated 4 2 2 1 1 2 2 0 2 3 4 0
Moderately differentiated 79 14 58 17 2 33 28 2 14 74 70 9
Poorly differentiated 17 6 11 4 1 8 6 1 3 16 16 2
p-value 0.215 0.847 0.807 0.561 0.686 0.855 0.396 0.398 0.843 0.764 0.781
Adenocarcinoma 119 52 79 49 6 41 48 3 6 110 97 6
Well differentiated 29 11 17 14 0 3 9 1 0 26 22 1
Moderately differentiated 64 24 38 23 4 25 30 1 0 66 58 0
Poorly differentiated 26 9 14 8 2 13 9 1 6 18 17 5
p-value 0.408 0.313 0.297 0.13 0.001 0.366 0.805 0.002 0.803 0.017 0.909
T status
T1 57 21 36 21 2 18 22 1 10 55 53 3
T2-3 162 53 114 50 8 66 62 5 15 148 138 14
p-value 0.049 0.98 0.168 0.73 0.608 0.172 0.259 0.471 0.741 0.739 0.414
Regional lymph node status
N0 141 48 98 42 6 52 46 5 14 129 119 11
N1-3 78 26 52 29 4 32 38 1 11 74 72 6
p-value 0.535 0.037 0.733 0.948 0.378 0.049 0.964 0.523 0.469 0.699 0.454
Clinical stage
I 135 57 113 54 8 62 62 5 19 149 141 12
II-III 84 17 37 17 2 22 22 1 6 54 50 5
p-value 0.038 0.012 0.822 0.657 0.436 0.983 0.714 0.946 0.135 0.127 0.19
Total 219 74 150 71 10 84 84 6 25 203 191 17
Table 2. Molecular expression profiles
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teins, p16 was expressed in 74 of 219 (33.8%) cases (Fig. 1A).
There were significant differences in T status and clinical
stage between the p16-positive and -negative patients (p=
0.049 and 0.038, respectively); normal p16 expression was
more frequent in patients with T1 than in those with T2-3
(36.8% vs. 32.7%), and in patients with stage I than in pa-
tients with stage II-III (42.2% vs. 20.2%). Seventy-four tu-
mors (68.5%) expressed p21. p21 expression was correlated
with regional lymph node status (p=0.037) and with clini-
cal stage (p=0.012). p27 immunoreactivity was identified
in 71 cases (32.4%) and was more common in adenocarci-
nomas than in squamous cell carcinomas (p=0.035). Cyclin-
B1 immunostaining was detected in 10 tumors (4.6%) with-
out a clinically significant pattern. Cyclin E was positive in
84 samples (38.4%). In adenocarcinomas, cyclin-E staining
was associated with differentiation (p=0.001); 3 of 29 well-
differentiated tumors (10.3%), 25 of 64 moderately differ-
entiated tumors (39.1%), and 13 of 26 poorly differentiated
tumors (50%) were positive for cyclin-E (data not shown).
For Ki-67, a high Ki-67 proliferative index was observed in
17 of 219 patients (7.8%). 
Of the apoptotic factors analyzed in the study, caspase-3
was expressed in 84 tumors (38.4%). Reactivity for caspase-
3 was present in 46 of 141 node-negative patients (32.6%)
and 38 of 78 node-positive patients (48.7%) (p=0.049). Sur-
vivin expression was rarely seen, with a mere positive stain-
Fig. 1. Immunohistochemistry for p16 (A) and bcl-2 (B), showing diffuse strong reactivity (×40).
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Fig. 2. Kaplan-Meier survival plots for non-small cell lung carcinoma. (A) p16 positive (solid line) vs. negative (dotted line); (B) bcl-2 posi-
tive (solid line) vs. negative (dotted line). p-values by Mantel-Cox log-rank test were 0.071 (A) and 0.047 (B).
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ing rate of 2.7%. bcl-2 immunoreactivity was observed in
25 cases (11.4%) (Fig. 1B). 
Of 219 patients, 203 (92.7%) and 191 (87.2%) had posi-
tive immunohistochemical staining for VEGF and endostatin,
respectively. There was no significant influence of these two
factors on histology, T status, regional lymph node status and
clinical stage.
Five-year survival rates according to clinicopathologic vari-
ables and immunohistochemical expression profiles are sum-
marized in Table 3. T status (53% vs. 44%; p=0.022), regional
lymph node status (58% vs. 32%; p=0.004) and clinical stage
(58% vs. 36%; p=0.006) demonstrated a significant corre-
lation with 5-yr survival, respectively, based on the log-rank
test.
Of 11 markers analyzed, p16 and bcl-2 had an impact on
the 5-yr survival. There was a trend for p16 immunoreac-
tivity to be associated with a good prognosis (5-yr survival,
57% vs. 42%; p=0.071). Patients with negative or positive
bcl-2 expression had 5-yr survival rates of 45% and 65%,
respectively, which was statistically significant (p=0.047,
Mantel-Cox log-rank test) (Fig. 2). 
Combined analysis of bcl-2 and p16 expression identified
5-yr survival rates of 73.3% and 38.6% in patients with at
least one of these factors and those with neither of these fac-
tors, respectively. These molecular phenotypes had a signifi-
cant influence over clinical outcome (p=0.002). In addition,
Hazard ratio was used to estimate hazard of death due to
NSCLC for the baseline variables (Table 4). The hazard of
death for node-positive patients was 1.855 times of the haz-
ard of death for node-negative patients (p=0.004). The haz-
ard of death for patients with tumor stages II-III was 1.994
times of the hazard of death for patients with tumor stage I
(p=0.002). For the effects on survival, bcl-2 expression was
statistically significant with a p-value of 0.029. The multivari-
ate analysis for overall survival revealed three independent
prognostic factors: regional lymph node status, stage and bcl-
2 expression. Regional lymph node status (N1-2 vs. N0) was
a significant and independent unfavorable prognostic factor
(p=0.043), as was the advanced clinical stage (II-III vs. I) (p=
0.003), whereas immunohistochemical expression of bcl-2
(positive vs. negative) was a significant and independent favor-
able prognostic factor (p=0.047).
DISCUSSION
Management of a patient with NSCLC could be determin-
ed by the aggressiveness of the cancer, and the aggressive can-
cer phenotypes are characterized by a number of molecular
abnormalities. Because of the complexity of the molecular
biology of NSCLC, studies on a single molecular factor have
not yet been successful in creating biological risk assessment.
A few studies support the possibility that multiple markers
might be more informative than any single marker for the
prediction of clinical outcome of NSCLC (4, 8). This has
prompted us to investigate 11 biologic markers, including
those involved in cell cycle control and proliferation, apop-
tosis and angiogenesis, and to construct a multivariate anal-
ysis for these factors predicting the patients’ prognosis.
The major findings of our study are as follows: 1) expres-
sion of p16 was associated with T status in NSCLC; 2) expres-
sion of p21 or caspase-3 correlated with regional lymph node
status; 3) expression of p16 or p21 correlated with stage; 4)
patients with positive bcl-2 immunostaining or p16 immu-
noreactivity or both had a higher 5-yr survival rate; 5) bcl-2
expression constitutes an independent prognostic parameter,
along with regional lymph node status and stage.
Cyclin E is involved in the regulation of G1-S transition
of the cell cycle, whereas cyclin B1 is involved in the regula-
tion of G2-M transition. An important mechanism for regu-
lating the CDK activity involves the CDK inhibitors, includ-
SCC, squamous cell carcinoma; AC, adenocarcinoma; VEGF, vascular
endothelial growth factor.
No. of patients
(N=219)
5-yr
survival (%)
p-value Variables
Age <65 92 47 0.538
≥65 127 48
Gender Male 168 49 0.912
Female 51 45
Histology SCC 100 47 0.815
AC 119 46
T T1 57 53 0.022
T2-3 162 44
N N0 141 58 0.004
N1-2 78 32
Stage I 135 58 0.006
II-III 84 36
p16 Positive 74 57 0.071
Negative 145 42
p21 Positive 150 53 0.104
Negative 69 46
p27 Positive 71 45 0.803
Negative 148 47
Cyclin B1 Positive 10 42 0.541
Negative 209 48
Cyclin E Positive 84 52 0.383
Negative 135 46
Ki-67 Positive 17 49 0.837
Negative 202 47
Caspase Positive 84 53 0.1
Negative 135 43
Survivin Positive 6 28 0.852
Negative 213 49
Bcl-2 Positive 25 65 0.047
Negative 194 45
VEGF Positive 203 48 0.873
Negative 16 46
Endostatin Positive 191 48 0.81
Negative 28 50
Table 3. Five-year survival rate analysis (log-rank test) according
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ing p21, p27, p57, p16, p18 and p19. Some of the alterations
in expression of these proteins, which lead to the failure of
cell cycle arrest, have been demonstrated to be predictive for
outcome and thus may serve as markers of more malignant
phenotypes (27). In the present study, p16 and p21 were
found to correlate with T, N or stage. Only p16 had a direct
impact on the 5-yr survival in patients with NSCLC. This is
in agreement with the results of the study by Esposito et al.
(8). In their multivariate analysis on cell cycle regulator pro-
teins, the only immunohistochemical parameter that influ-
enced overall survival was p16. It is suggested that cell cycle
regulatory proteins may have different and multifunctional
properties on cell proliferation and may contribute to their
different effects on survival. The p16 expression may have a
great value in identifying NSCLC patients with better prog-
nosis.
As bcl-2 inhibits apoptosis, the bcl-2 overexpression should
theoretically favor the malignant process and result in a poor
outcome. However, there have been several studies describ-
ing a favorable outcome in NSCLC expressing bcl-2, although
others have shown no survival advantage or even a worse prog-
nosis (14, 26-29). Poleri et al. (26) described a poor outcome
in patients with positive bcl-2 tumor. Cox et al. (14) inves-
tigated 167 patients with resected stage I-IIIA NSCLC and
found a trend for bcl-2 expression to be associated with an
improved survival, which was consistent with our findings.
The reasons for this association are poorly understood. These
conflicting results may have been due to the difference in
the nature of tumor samples analyzed. In contrast to Poleri
et al’s. study limited to the stage I NSCLC (26), we includ-
ed stage I-IIIA tumors, as in Cox et al. (14). The criteria for
interpreting the results as positive or negative may also have
attributed to this difference. Cytoplasmic bcl-2 staining was
considered either positive or negative according to the inves-
tigators using different percentage criteria. While only sam-
ples with at least 20% of the tumor were regarded as being
positive, immunoreaction in more than 5% or even 1% of
the tumor cells was also considered as being expressed by
Variables Hazard ratio 95% CI for HR p-value Level
A. Univariate analysis of potential prognostic factors
Age (yr) ≥65 vs. <65 0.874 0.570-1.341 0.539
Histology AC vs. SCC 0.951 0.623-1.452 0.815
T  T2-3 vs. T1 1.604 0.987-2.605 0.056
N N1-2 vs. N0 1.855 1.214-2.834 0.004
Stage II-III vs. I 1.994 1.282-3.101 0.002
p16 Positive vs. negative 0.65 0.406-1.041 0.065
p21 Positive vs. negative 0.697 0.450-1.079 0.106
p27 Positive vs. negative 1.061 0.665-1.694 0.803
Cyclin B1 Positive vs. negative 1.325 0.536-3.270 0.542
Cyclin E Positive vs. negative 0.82 0.525-1.281 0.384
Caspase Positive vs. negative 0.686 0.437-1.075 0.095
Survivin Positive vs. negative 1.116 0.352-3.536 0.852
Bcl-2 Positive vs. negative 0.44 0.192-1.011 0.029
VEGF Positive vs. negative 0.929 0.374-2.303 0.873
Endostatin Positive vs. negative 0.925 0.491-1.744 0.811
Ki-67 Positive vs. negative 0.91 0.367-2.252 0.878
B. Multivariate analysis of prognostic factors
Age (yr) ≥65 vs. <65 0.924 0.574-1.485 0.743
Histology AC vs. SCC 0.913 0.532-1.566 0.74
T  T2-3 vs. T1 1.065 0.531-2.137 0.859
N N1-2 vs. N0 1.821 1.019-3.292 0.043
Stage II-III vs. I 1.999 1.282-3.101 0.003
p16 Positive vs. negative 0.697 0.414-1.174 0.088
p21 Positive vs. negative 0.942 0.571-1.555 0.816
p27 Positive vs. negative 1.117 0.661-1.886 0.68
Cyclin B1 Positive vs. negative 1.687 0.544-5.227 0.365
Cyclin E Positive vs. negative 0.894 0.518-1.543 0.687
Caspase Positive vs. negative 0.717 0.395-1.302 0.275
Survivin Positive vs. negative 0.975 0.222-4.293 0.974
Bcl-2 Positive vs. negative 0.42 0.168-1.049 0.047
VEGF Positive vs. negative 1.063 0.365-3.096 0.911
Endostatin Positive vs. negative 1.1 0.502-2.410 0.812
Ki-67 Positive vs. negative 0.827 0.319-2.140 0.695
Table 4. Cox proportional hazards model analysis of prognostic factors in patients with NSCLC
CI, confidence interval; HR, hazard ratio; AC, adenocarcinoma; SCC, squamous cell carcinoma.324 J. Yoo, J.H. Jung, M.A. Lee, et al.
others (14, 30, 31). Further investigations using the identi-
cal scoring criteria are necessary to establish a significance of
bcl-2 expression in lung cancer outcome.
The bcl-2 expression has been demonstrated to be inversely
related with angiogenesis, a finding that may account for
the favorable prognosis. The present study, however, revealed
a significant association between the bcl-2 immunoreactivi-
ty and VEGF (data not shown), suggesting that other mech-
anisms independent of the angiogenesis pathway may account
for a better survival in patients with bcl-2 positivity. It has
been suggested that loss of bcl-2 expression may represent
tumor de-differentiation (14, 32).
VEGF is a potent growth factor for endothelial cells. While
angiogenesis and increased VEGF have been shown to adver-
sely affect NSCLC outcome by some authors, other studies
showed no prognostic value of VEGF (27). We found no cor-
relation between VEGF immunoreactivity and prognosis.
Endostatin, one of angiogenic inhibitors, controls growth
by suppressing endothelial cell proliferation and angiogene-
sis and by indirectly increasing apoptosis in tumor cells. The
expression of endostatin has been demonstrated in several
solid malignancies, including rectal cancer, ovarian cancer,
hepatocellular carcinoma and NSCLC (17, 27, 33). Although
higher expression of endostatin would be expected to improve
survival, the impact of endostatin expression on clinical out-
come remains unclear. Iizasa et al. (17) reported that the ex-
pression of collagen XVIII, an endostatin precursor, in tumor
tissue correlated with elevated levels of circulating serum endo-
statin and was strongly associated with a poorer outcome in
NSCLC. In this study, the majority of NSCLC cases demon-
strated endostatin immunoreactivity. However, no statisti-
cally significant effect on survival was found.
In conclusion, the present study demonstrated that NSCLCs
have heterogeneous expression of cell cycle regulatory pro-
teins, apoptotic factors, and angiogenic factors. However, the
expressions of p16 and bcl-2 were associated with a trend
toward a better survival in this selected group of patients.
These findings warrant additional molecular and clinicopatho-
logic studies of those markers and their related pathways
potentially relevant to prognosis in NSCLC. 
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